VolitionRX (VNRX)
:VNRX
Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.18
$0.01(1.52%)
At close: 4:00 PM EST
$0.18
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.15 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)19.46M
Market Cap
$27.10M
Enterprise Value$27.97M
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$11.46M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding158,481,250
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.81
P/FCF Ratio-1.38
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue16.19
Enterprise Value/Gross Profit16.19
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$2.00Price Target Upside1011.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$9.19M
Bulls Say, Bears Say
Bulls Say
Biomarker SpecificityTargeting cancer-specific DNA regions bound by the CTCF protein could enable more tissue-specific cancer detection, supporting development of multi-cancer early screening and treatment monitoring applications.
Innovative Detection MethodCapture-Seq's enrichment approach that isolates circulating tumor DNA offers a technical advantage that may improve detection accuracy over existing liquid biopsy methods and attract partner interest.
Licensing PartnershipsOngoing discussions with multiple diagnostic and liquid biopsy companies could lead to licensing deals that provide new revenue streams and accelerate commercial adoption.
Bears Say
Capital NeedsRequirement for additional capital to fund operations increases the risk of dilution or financing strain that could pressure the stock if funding terms are unfavorable.
Financial PerformanceRevenue missed projections and net loss was larger than expected, highlighting near-term operating challenges that may weigh on investor confidence and valuation.
Share Dilution ConcernsAnalyst's price target was lowered mainly due to increased share count, signaling dilution concerns that can reduce per-share value and temper investor enthusiasm.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.15 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $27.10M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is May 13, 2026 which is in 22 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Mar 31, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.038 by -$0.012.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VolitionRX have?
VolitionRX has 158,481,250 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.038. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and commercial progress across multiple pillars—CE‑marked product revenue, government‑backed interventional study inclusion, a >99% pure ctDNA Capture‑Seq breakthrough, new partner agreements, veterinary automation advances, and multiple peer‑reviewed publications. At the same time, the company remains in early commercialization with a small absolute revenue base ($1.7M), lumpy revenues, significant cash burn ($19.7M net cash used) and a low year‑end cash balance partially addressed by subsequent financings. Scaling depends on successful licensing, reimbursement (notably France expected Q4 2026) and larger validation studies. On balance, the call emphasized transformative technology and clear commercialization traction while acknowledging near‑term execution and funding risks.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.00
▲(1011.11% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.10% Mutual Funds
0.17% Other Institutional Investors
88.35% Public Companies and
Individual Investors